preprint
<title>Abstract</title> In this work 7-Acetyl-4-cyano-1, 6-dimethyl-6-hydroxy-8-(2-nitrophenyl)-5,6,7,8-tetrahydrosoquinoline-3(2 <italic>H</italic> )-thione compound <bold>2</bold> was synthesized and used as starting materials. Subsequently, Compounds <bold>3–7</bold> were produced through its reaction with ethyl iodide, ethyl chloroacetate, chloroacetonitrile, and chloroacetaldehyde. Additionally, compound <bold>2</bold> and 2-chloroacetamide were heated in ethanol with sodium acetate trihydrate present, resulting in the formation of 3-Substituted methylthio-5,6,7,8-tetrahydroisoquinoline-4-carbonitriles <bold>9a–d</bold> , respectively. Similarly, compounds <bold>2</bold> and N-(1-naphthyl)-2-chloroacetamide reacted to produce high yields of the equivalent N-(1-naphthyl)-(5,6,7,8-tetrahydroiso-quinolin-3-ylthio)acetamides <bold>9e</bold> . Compounds <bold>9a–e</bold> were cyclized into their <bold>10a</bold> and <bold>d.</bold> Using elemental analysis and spectral data (FT-IR, <sup>1</sup> H NMR, and <sup>13</sup> C NMR). All newly synthesized compounds were described. The anticancer activity of the produced compounds was also assessed against eight cell lines at one spot concentration and one normal human skin fibroblast cell line <bold>HSF</bold> . Then determine the IC <sub>50</sub> of our drugs against two specific cell lines using various doses. Compound <bold>3</bold> is the most effective chemical against <bold>HEGP2</bold> , according to our research. Compound <bold>9c</bold> was also the most effective compound against <bold>HCT116</bold> . For generally, the tested substances showed moderate anticancer activity, according to the data. The effects of compound <bold>3</bold> on the proliferation of HEGP2 cell lines were then investigated using an apoptotic Annexin V-FITC assay and flow cytometry. Compound <bold>3</bold> increased the HEGP2 cell line's apoptosis by 50 times and caused cell cycle arrest at the G2/M phase.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.21203/rs.3.rs-4493252/v2
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.